---
title: "Medication Link to Sudden Vision Loss Found in Diabetes Patients"
url: https://noti.group/medication-link-to-sudden-vision-loss-found-in-diabetes-patients/
language: en
publisher: "Noti Group"
section: "Health"
published: 2026-10-15T04:14:55.000Z
updated: 2026-10-15T10:27:01.976Z
id: 92c6d651-dfc5-4280-a557-0c8d0b9dfd85
source: "ScienceDaily Health https://www.sciencedaily.com/releases/2026/10/261014015521.htm"
attribution: "Link to https://noti.group/medication-link-to-sudden-vision-loss-found-in-diabetes-patients/ and name Noti Group when you quote or summarize this story."
---

# Medication Link to Sudden Vision Loss Found in Diabetes Patients

Researchers at Rutgers have discovered a link between two widely used medications, Ozempic and Wegovy, and an increased risk of ischemic optic neuropathy, which can cause sudden vision loss.

Researchers at Rutgers have made a concerning discovery about two widely used medications for diabetes and weight loss: Ozempic and Wegovy may be linked to an increased risk of sudden vision loss in some patients.

The condition behind this risk is ischemic optic neuropathy, which occurs when the optic nerve - responsible for transmitting visual information from the eye to the brain - suffers damage due to reduced blood flow. This can result in significant vision problems.

A study analyzing data from a large database of US adults with Type 2 diabetes has found that people taking these medications may face a slightly higher risk of developing ischemic optic neuropathy compared to others. The researchers focused on patients who had recently started using GLP-1 receptor agonists, a class of drugs that includes semaglutide.

These medications are sold under various brand names, including Ozempic and Wegovy for semaglutide, and have been shown to help manage blood sugar levels and weight in addition to reducing cardiovascular and kidney problems.

The research team discovered that GLP-1 medications are associated with a slightly increased likelihood of ischemic optic neuropathy, a condition that can cause sudden vision loss.

According to Chintan Dave, a core faculty member at Rutgers Institute for Health, the risk is small but clinically significant because it can result in permanent vision impairment. The study found that approximately three to four additional cases per 10,000 patients treated with GLP-1s over 18 months were linked to this condition.

The absolute risk of ischemic optic neuropathy remains low, but its growing prevalence makes continued safety monitoring crucial due to the widespread use of these medications in both people with and without Type 2 diabetes. These drugs have become increasingly popular among patients seeking to manage their blood sugar levels and weight.

The study identified patterns among patients who developed ischemic optic neuropathy, revealing that cases were more common among men and adults aged 50 to 65. This demographic may require closer monitoring due to the potential for sudden vision loss.

Early recognition of symptoms and prompt ophthalmologic evaluation are essential for patients at higher baseline risk, as ischemic optic neuropathy can present with permanent vision impairment.

Ischemic optic neuropathy is a rare but serious condition that affects the optic nerve, leading to potentially permanent vision loss. In most cases, this occurs due to inadequate blood supply to the front portion of the optic nerve, causing damage and impairing vision.

The resulting vision impairment can be severe, with some patients experiencing complete blindness. However, in approximately one-third of cases, affected individuals may experience some recovery within the first six months following onset. Even when improvement does occur, a significant degree of visual impairment often persists.

Patients who develop ischemic optic neuropathy typically notice sudden changes in their vision, including blurriness, dimming, or missing areas in their field of view. This condition usually affects part of the vision in one eye, rather than causing complete blindness.

While the study's findings suggest a link between GLP-1 medications and an increased risk of ischemic optic neuropathy, researchers emphasize that more research is needed to determine whether these medications directly contribute to the condition. Other factors, such as underlying health conditions, may also play a role in the observed association.

Research on medications Ozempic and Wegovy has uncovered an unexpected side effect: a rare risk of sudden vision loss.

Investigating this phenomenon further, researchers have found that individuals taking these diabetes treatments are more likely to experience eye damage, particularly in the form of retinal vein occlusion, which can lead to permanent vision impairment.

Further analysis reveals that other factors may also contribute to this increased risk, including underlying health conditions.

---
Source: [ScienceDaily Health](https://www.sciencedaily.com/releases/2026/10/261014015521.htm)  
Published by Noti Group: https://noti.group/medication-link-to-sudden-vision-loss-found-in-diabetes-patients/